---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000063"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-06-18T11:02:51+00:00"
generated_at: "2026-06-18T11:05:04.325486+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model

## Summary
- KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).
- Suppression persisted through treatment and washout; no impairment of normal electrical transmission.
- Data presented at Epilepsy Foundation Pipeline Conference, June 18-19, 2026 in Leesburg, VA.
- KIO-300 is the active ingredient of KIO-301, currently in Phase 2 for Retinitis Pigmentosa.
- CEO cites broad therapeutic potential beyond ophthalmology; full rights retained outside eye.

## SEC filing metadata
- accession: 0001372514-26-000063
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-06-18T11:02:51+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/0001372514-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/kprx-20260618.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000063
- JSON: https://secwatch.observer/filing/0001372514-26-000063.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.